

Nomination committee's proposal to the annual general meeting 2009

The nomination committee of Biovitrum AB (publ), which has consisted of Håkan Åström (chairman of the board of directors), Henrik Lif (representing Nordic Capital and chairman of the nomination committee), Nicholas J. Simon (representing MPM Capital), and Ekaterina Smirnyagina (representing Alta Partners) proposes:

- that Bertil Villard from Advokatfirman Vinge is elected chairman of the Meeting,
- that fees to be paid to the board of directors should amount to SEK 2,650,000, to be allocated with SEK 950,000 to the chairman and SEK 250,000 to each other board member, that fees for work in the audit committee should be SEK 50,000 to the chairman and SEK 25,000 to each other member of such committee, that no fees should be paid for work in the compensation & benefit committee and that fees for work in the science committee should be SEK 50,000 to the chairman and SEK 25,000 to each other member of such committee,
- that the fees to the auditor should be paid in accordance with normal standards and approved invoice,
- that seven ordinary board members without deputies should be appointed,
- that the board members Håkan Åström, Mats-Olof Ljungkvist, Wenche Rolfsen, Michael Steinmetz and Hans Wigzell should be re-elected, that Peter Sellei and Hans Glemstedt should be elected as new board members and that Håkan Åström should be appointed chairman of the board of directors.

Anders Hultin and Toni Weitzberg have declined re-election. Peter Sellei is responsible for the Healthcare Sector in the Core Investment Department at Investor AB and former thoracic surgeon at Karolinska Hospital and pharma analyst. Sellei has an M.D. from Karolinska Institutet. Hans Glemstedt is a team member in the Operating Investment group of Investor AB and former Senior Manager at McKinsey. Glemstedt has a graduate and MBA from Stockholm School of Economics.

The shareholders are informed that the annual general meeting 2007 elected PricewaterhouseCoopers AB as the auditor of the company for the time until the end of the annual general meeting 2011.

The nomination committee in March 2009